When Medivation bidders were circling, CEO David Hung fought hard for a higher price for the company’s shareholders. And he was one of them–a big one, as a new securities filing shows.
Hung stands to collect more than $300 million when Pfizer closes on its $14 billion deal for Medivation, thanks to his years of accumulated stock, options, incentive-plan shares and the like.
As of Aug. 18, Hung held 2.84 million stock options, vested and unvested, worth $182 million in the Medivation sale. He owned 1.45 million shares outright, worth another $118.6 million. His incentive-plan share units amounted to 171,528, for a cash value of almost $14 million.
Then there are Hung’s stock appreciation rights, which, like options, benefit executives when share prices rise. They’re worth $37 million.
His cash severance is peanuts, comparatively–24 months of base salary, or about $1.82 million, according to the company’s securities filing, plus an estimated performance bonus of more than $868,000.
Grand total: About $354 million.
That’s a nice payoff for Hung, who co-founded Medivation in 2003 and spent 13 years building it into a company that could sell for $14 billion. Enough to retire to a private island somewhere, or, more likely, start up another biotech venture.
In the realm of biopharma payouts, it’s hefty. Henri Termeer, who was CEO of Genzyme when Sanofi snapped up his company for $20 billion, bowed out with $158 million in payment for stock, options, performance units and severance benefits.
But if you want to get technical about it, the “golden parachute” part of Hung’s figure is $35.6 million. That amount includes the cash severance and bonus, plus the payoff from unvested options and performance shares, as well as the value of continued health insurance benefits.
Here’s how some other exits compare: David Pyott, CEO of Allergan till Actavis bought the company and assumed its name, was in line for a $100 million goodbye payment along the same lines. Currently Allergan CEO Brent Saunders boasts a $140 million parachute, per Bloomberg’s recent calculations. The cash portion of his severance amounts to $12.2 million alone.
And according to FiercePharma research, Wyeth CEO Bernard Poussot, who also sold his company to Pfizer, exited with $53 million. Schering-Plough’s Fred Hassan, CEO when Merck & Co. pulled off their merger, left with almost $50 million; Schering even covered related taxes, to the tune of $11.7 million.
By Tracy Staton
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.